July 22, 2019 / 11:40 PM / 2 months ago

FTC fights AbbVie appeal of $493 million award over 'sham' AndroGel litigation

The Federal Trade Commission is urging a federal appeals court to hold that patent lawsuits AbbVie Inc filed against companies seeking to make generic competitors to its testosterone replacement drug AndroGel were baseless “shams.”

The FTC on Friday asked the 3rd U.S. Circuit Court of Appeals to uphold a ruling that required AbbVie and a smaller drugmaker to pay $493 million for engaging in anticompetitive conduct that delayed the release of generic versions of AndroGel.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2Z9iMbM

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below